Clinical trials
Observational Chikungunya Fever trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 6 |
| 2017 | 2 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 3 |
| 2023 | 1 |
| 2025 | 6 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Unknown status | 4 |
| Enrolling by invitation | 3 |
| Active, not recruiting | 3 |
| Withdrawn | 2 |
| Recruiting | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Valneva Austria GmbH | 4 |
| Centre Hospitalier Universitaire de la Réunion | 3 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| University Hospital Center of Martinique | 2 |
| University of Heidelberg Medical Center | 2 |
| Cepheid | 1 |
| George Washington University | 1 |
| Guangzhou University of Traditional Chinese Medicine | 1 |
| Hospital Israelita Albert Einstein | 1 |
| Institut Pasteur | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chikungunya Fever | 28 |
| Dengue | 15 |
| Zika Virus Infection | 13 |
| Malaria | 4 |
| Arbovirus Infections | 3 |
| Fever | 2 |
| Guillain-Barre Syndrome | 2 |
| Leptospirosis | 2 |
| Measles | 2 |
| Meningitis | 2 |
Trials
Showing 26 to 28 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.